EKA at Biology Products
EKA at Biology Technology
EKA at Medicine News
Hepatitis B Drug Tyzeka Approved By FDA
On Wednesday, the US Food and Drug Administration gave its approval for Tyz
eka (telbivudine) manufactured by Novartis Pharma to be used in the treatment of chronic Hepatitis B// (HBV). Clinical studies have shown that the drug does not have serious side effects and is usually well tolerated. Hepatitis B is a viral infection affecting the liver and infects about 70,000 Americans every...
Novagali Pharma Presents Phase III Clinical Trial of Vekacia(R) for Vernal Keratoconjunctivitis
Novagali Pharma, an emerging pharmaceutical company specialized in ophthalmology presents positive results of its pivotal phase III clinical trial positive results from the Phase III clinical study of V
ekacia(R) in children suffering from Vernal Keratoconjunctivitis (VKC) at the XIV Afro-Asian Congress of ophthalmology (AACO) held from June 20 to 25 2007 in Marrakech (Morocco). VKC...
EKA at Medicine Products
EA/EKA Series
Description:With the simplicity of one touch design all of your sterilization and drying needs are fulfilled. The Tuttnauer fully automatic autoclaves fill, sterilize, exhaust and dries at the touch of a button. All EA and
EKA models feature a closed door active drying system to maintain sterility and ensure efficient drying of packs and pouches....
Company:Tuttnauer Co. Ltd.
Prekallikrein Factor, Activity
Description:ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, maj...
Company:ARUP Laboratories
EKA at Medicine Technology
Novagali Pharma Presents at AACO the Results of its Pivotal Phase
III Clinical Trial of Vekacia in Children Suffering From Vernal
Keratoconjunctivitis
EVRY, France, June 25, 2007 /PRNewswire/ -- Novagali Pharma, anemerging pharmaceutical company specialized in ophthalmologypresents positive results of its pivotal phase III clinical trialpositive results from the Phase III clinical study of V
ekacia(R) inchildren suffering from Vernal Keratoconjunctivitis (VKC) at theXIV Afro-Asian Congress of ophthalmology (AACO) held from June 20to 25...
Novagali Pharma Announces Positive Vekacia Clinical Results From
Pivotal Phase III Trial in Vernal Keratoconjunctivitis
EVRY, France, April 04, 2007 /PRNewswire/ -- Novagali Pharma, anemerging ophthalmic pharmaceutical company specialized inophthalmology, announces today positive results from the Phase IIIclinical study of V
ekacia(R) in children suffering from VernalKeratoconjunctivitis (VKC). In this orphan disease, it was shownthat both symptoms and signs of disease improved in patientsreceiving V
ekacia...